Brokerages Set Definitive Healthcare Corp. (NASDAQ:DH) PT at $2.47

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have received an average rating of “Reduce” from the nine analysts that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation, one has assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $2.4714.

DH has been the topic of several recent analyst reports. Bank of America reaffirmed an “underperform” rating and issued a $0.70 price target on shares of Definitive Healthcare in a research note on Monday, June 29th. Barclays cut their price objective on Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research report on Monday, March 30th. Robert W. Baird set a $1.10 target price on shares of Definitive Healthcare in a research report on Friday, May 8th. Zacks Research raised shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday, June 3rd.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds have recently made changes to their positions in the stock. Williams & Novak LLC raised its position in Definitive Healthcare by 155.8% in the second quarter. Williams & Novak LLC now owns 78,610 shares of the company’s stock valued at $65,000 after purchasing an additional 47,880 shares during the period. Irenic Capital Management LP acquired a new stake in shares of Definitive Healthcare in the first quarter valued at $71,000. Flywheel Private Wealth LLC acquired a new stake in shares of Definitive Healthcare in the first quarter valued at $83,000. Invesco Ltd. raised its holdings in shares of Definitive Healthcare by 5.8% in the 4th quarter. Invesco Ltd. now owns 117,427 shares of the company’s stock valued at $337,000 after buying an additional 6,400 shares during the period. Finally, XTX Topco Ltd raised its holdings in shares of Definitive Healthcare by 57.5% in the 4th quarter. XTX Topco Ltd now owns 75,306 shares of the company’s stock valued at $216,000 after buying an additional 27,495 shares during the period. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Stock Down 9.8%

Shares of NASDAQ DH opened at $0.81 on Thursday. The company has a 50 day simple moving average of $0.85 and a 200-day simple moving average of $1.40. The company has a market capitalization of $85.67 million, a P/E ratio of -0.50, a P/E/G ratio of 11.99 and a beta of 1.33. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.70.

Definitive Healthcare (NASDAQ:DH) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $55.93 million for the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. On average, equities research analysts predict that Definitive Healthcare will post 0.05 earnings per share for the current year.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.